Key Points
- Tcg Crossover Gp II, LLC bought 17,763 shares of Surrozen on Feb. 11 at an average price of $23.57 for a total of $418,673.91, taking its direct holding to 650,567 shares (a 2.81% increase) valued at about $15.33 million.
- The same investor made multiple purchases in late January–February — roughly 28,213 shares totaling about $647k — indicating sustained insider accumulation.
- For context, Surrozen has a market cap of about $209.8 million and opened at $24.48 (near its one‑year high of $25.84); analysts are mixed but the consensus is a “Moderate Buy” with an average target of $32.00.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc bought 1,093 shares of Surrozen stock in a transaction that occurred on Thursday, February 12th. The shares were acquired at an average price of $23.86 per share, for a total transaction of $26,078.98. Following the acquisition, the insider directly owned 651,114 shares in the company, valued at approximately $15,535,580.04. This represents a 0.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Tcg Crossover Gp Ii, Llc also recently made the following trade(s):
- On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc acquired 17,763 shares of Surrozen stock. The stock was bought at an average cost of $23.57 per share, for a total transaction of $418,673.91.
- On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were bought at an average price of $21.94 per share, for a total transaction of $95,548.70.
- On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The stock was bought at an average price of $21.38 per share, with a total value of $15,628.78.
- On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The shares were purchased at an average price of $21.39 per share, for a total transaction of $91,356.69.
Surrozen Trading Down 1.4%
NASDAQ SRZN opened at $24.48 on Friday. The stock has a market cap of $209.79 million, a P/E ratio of -1.10 and a beta of 0.58. The company's fifty day simple moving average is $21.59 and its 200-day simple moving average is $15.75. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $25.84.
Wall Street Analyst Weigh In
A number of research analysts recently commented on SRZN shares. Wall Street Zen raised Surrozen to a "sell" rating in a report on Friday, November 28th. Lifesci Capital upgraded Surrozen to a "strong-buy" rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Surrozen in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Surrozen currently has a consensus rating of "Moderate Buy" and a consensus price target of $32.00.
Check Out Our Latest Analysis on Surrozen
Hedge Funds Weigh In On Surrozen
A number of hedge funds have recently added to or reduced their stakes in SRZN. Geode Capital Management LLC increased its stake in Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. Stonepine Capital Management LLC raised its stake in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company's stock worth $2,736,000 after acquiring an additional 20,247 shares during the period. Stempoint Capital LP lifted its holdings in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company's stock worth $6,138,000 after acquiring an additional 445,713 shares during the last quarter. Armistice Capital LLC bought a new position in Surrozen in the second quarter worth about $536,000. Finally, Braidwell LP acquired a new position in Surrozen in the second quarter valued at approximately $1,252,000. Institutional investors and hedge funds own 66.57% of the company's stock.
Surrozen Company Profile
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
